Stock 6492 SENHWA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Senhwa Biosciences, Inc. Stock

Equities

6492

TW0006492002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
41.9 TWD +0.36% Intraday chart for Senhwa Biosciences, Inc. -3.79% -17.68%
Mar. 20 Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan CI
Mar. 14 Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 1M 30.83K Sales 2023 1M 30.83K Capitalization 4.54B 140M
Net income 2022 -350M -10.79M Net income 2023 -296M -9.12M EV / Sales 2022 3,537 x
Net cash position 2022 1.6B 49.42M Net cash position 2023 1.31B 40.36M EV / Sales 2023 3,230 x
P/E ratio 2022
-14.8 x
P/E ratio 2023
-15.3 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 74.53%
More Fundamentals * Assessed data

Chart Senhwa Biosciences, Inc.

Dynamic Chart

Latest news about Senhwa Biosciences, Inc.

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19 CI
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19 CI
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Senhwa Biosciences Receives Taiwan Fda Ind Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe Covid-19 CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC CI
More news

Press releases Senhwa Biosciences, Inc.

Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated) AQ
Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection AQ
Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19 AQ
Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others AQ
Sh : Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS AQ
More press releases

Quotes and Performance

1 day+0.36%
1 week-3.79%
Current month-4.99%
1 month-0.83%
3 months-10.18%
6 months-0.83%
Current year-17.68%
More quotes

Highs and lows

1 week
41.05
Extreme 41.05
43.00
1 month
41.05
Extreme 41.05
45.40
Current year
41.05
Extreme 41.05
51.80
1 year
41.00
Extreme 41
62.30
3 years
38.85
Extreme 38.85
206.00
5 years
38.85
Extreme 38.85
309.50
10 years
38.85
Extreme 38.85
309.50
More quotes

Managers and Directors - Senhwa Biosciences, Inc.

Managers TitleAgeSince
Tai Sen Soong CEO
 Chief Executive Officer - 12-11-15
Hsiao Ping Chang DFI
 Director of Finance/CFO - 12-12-31
Members of the board TitleAgeSince
Tai Sen Soong CEO
 Chief Executive Officer - 12-11-15
Chia Hung Li BRD
 Director/Board Member - 15-03-08
Benny Hu CHM
 Chairman 75 11-12-31
More insiders

Quotes

Date Price Change Volume
24-04-18 41.9 +0.36% 109,366
24-04-17 41.75 +1.21% 106,731
24-04-16 41.25 -2.48% 238,539
24-04-15 42.3 -2.31% 217,581
24-04-12 43.3 -0.57% 113,750

End-of-day quote Taipei Exchange, April 17, 2024

More quotes

Company Profile

Senhwa Biosciences, Inc. is a Taiwan-based company principally engaged in the research and development of anti-cancer new drugs and special drug substances. The Company's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The Company has not generated any revenues yet.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2025 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SENHWA BIOSCIENCES, INC. Stock Senhwa Biosciences, Inc.
-17.68% 115M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.73% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.76% 96.07B
ARGENX SE Stock argenx SE
-1.43% 21.66B
BIONTECH SE Stock BioNTech SE
-18.06% 20.77B
GENMAB A/S Stock Genmab A/S
-7.10% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.21% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.79% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.76% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6492 Stock